Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models

Unresectable hepatocellular carcinoma (uHCC) is one of the most lethal and prevalent cancers worldwide, and current systemic therapeutic options for uHCC are limited. Lenvatinib, a multiple receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFRs) and fibrobl...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuki, Masahiro, Hoshi, Taisuke, Yamamoto, Yuji, Ikemori‐Kawada, Megumi, Minoshima, Yukinori, Funahashi, Yasuhiro, Matsui, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010799/
https://www.ncbi.nlm.nih.gov/pubmed/29733511
http://dx.doi.org/10.1002/cam4.1517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010799/
https://www.ncbi.nlm.nih.gov/pubmed/29733511
http://dx.doi.org/10.1002/cam4.1517

Ejemplares similares